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Maine AIDS Care 
AIDS Consultation Service • Maine Medical Center • Winter 95-96 
New Drugs, New Combinations 
Show Promise 
Four new antiretroviral agents have been approved by the FDA since November 
1995. Three of these drugs (saquinavir, indinavir, and ritonavir) represent a potent new class 
of antiretroviral agents, the protease inhibitors. The fourth, lamivudine (3TC) is a new reverse 
transcriptase inhibitor. In addition, newly released data from 3 different studies docum~nt the 
benefits of antiviral combination therapies over zidovudine (AZT) mono therapy. What impact 
do these events have on current therapy for HIV? 
Benefit of Combination Therapy Supported 
On the basis of 3 studies (ACTG 175, Delta I & II), it appears that AZT 
monotherapy is no longer the initial treatment of choice in asymptomatic patients. 
Combination therapy (AZT & DDI, AZT & DDC) or DDI alone, delayed the onset of AIDS 
and improved mortality in asymptomatic patient_s where AZT alone di~ not. Wh~t is_not clear 
is what combinations will prove most effective. Of the currently available medication, AZT 
& DDI, AZT & DDC, and AZT & 3TC are all of proven efficacy. Others that show promise 
include DDI & D4T, and combinations that include protease inhibitors may prove to be the 
most effective. 
Role of Lamivudine (3TC or Epivir) 
Lamivudine, a reverse transcriptase inhibitor, has very limited effectiveness as 
monotherapy, but is synergistic with AZT, and appears to inhibit the development of AZT-
resistance among strains. The combination of AZT and 3TC appears well tolerated and 
effective in early clinical trials. Lamivudine has few side effects, although nau~ea ~nd 
neuropathy have been infrequently documented. A recent abstract suggests that lam1vudme 
may be rarely associated with neutropenia or anemia in patients with low CJ?4 ~ount~. 
However, as these patients had late stage HIV and were on an average of 4 medications, 1t 
is not certain that lamivudine induced these events. 
The combination of AZT, 3TC, and a protease inhibitor (indinavir) were remarkably 
potent in a small trial of 26 patients, 24 of whom were rendered aviremic at 6 months. 
Continued on Page 2 New Drug:s 
First Delavirdine 
(U-90) Study Results 
Presented 
At a recent investigators' meeting in 
Washington, DC in January, the initial 
results of all 3 protocols for the UpJohn 
Delavirdine (DL V) study were presented. 
Data for 2,300 patients from all 105 sites 
(ACS at MMC is one of the national multi-
center study sites) were presented on >400 
patients who have~ 1 year in the study. 
As a number of Maine patients participated 
in this trial we provide a detailed summary 
of these results. 
Summaty of Results 
1. Protocol 0021 (AZT+ DLV or AZT+ 
Placebo in Patients with CD4 Counts >200 
and AZT naive or < 6 Months Prior AZT 
Therapy): Three different doses of 
delavirdine were randomized among the 
patients receiving the experimental drug 
(200mg tid; 300mg tid; & 400mg tid). 
Highest blood levels of delavirdine were 
seen in the patients receiving 400mg tid. 
The best sustained CD4 cell increase was 
seen in the patients receiving 300 & 400mg 
tid. The HIV RNA viral load was decreased 
by 1.0 log with the 400 dose at 4 weeks. 
There was an increase in viral load by week 
8 to .5 log, but this .5 log overall decrease 
was sustained for 60 weeks. Therefore, 
UpJohn has made a decision to delete the 
200mg arm; the 0021 protocol will be 
converting all patients to the 400mg tid 
dose. In addition, patients who are receiving 
only AZT + placebo or AZT and DL V 
200mg or 300mg will be re-randomized to 
receive AZT+3TC+placebo or 
AZT+3TC+DL V 400mg tid. In addition, a 
Phase II (New Trial Design) will be 
implemented for approximately 450 patients 
in the following way: 
AZT+3TC+(DLV placebo) 
AZT+3TC+DL V 400mg tid 
AZT+DL V 400mg tid+(3TC placebo) 
see Delavirdine cont. on page 3 
AIDS Conference Offers Reason for Hope 
The just completed Third Conference on Retroviruses and Opportunistic I~ections in 
Washington, D.C. provided the stage for several new insights regarding the pathophys1ology and 
management of HIV disease. A number of promising findings from the past 18 months were 
supported or confirmed by new research. Key compo~en~ _offering hope and ex~ite~ent were: 
I . Information on a new class of drug (protease inhibitors) as well as combmabons of drugs 
that slow viral replication I regeneration significantly better than the standard 
monotherapies of the most recent past. (see New Drug8 page 1) 
2. Information on new tests that measure the actual am01mt of virus in the peripheral system 
as well as how the results of these findings can be used to manage treatment. 
Antiviral Therapy 
Data presented at the conference confirms that treating HIV infection wi~ a combina~on 
of antiviral drugs is generally more successful at achieving more complete vrrus suppression, 
leading to longer disease-free intervals, increased CD4 cell counts, limiting the emergence of drug-
resistant viruses, and treating established drug resistance. Combination therapy with selected 
reverse transcriptase inhibitors can lead to sustained antiviral efficacy and attenuated viral virulence. 
Analysis of survival improvements with combination anti-vital therapy were analyzed from 
a number of clinical trial and observational studies (ACTG 175, Delta, Glaxo Wellcome Trial, the 
MACS, and the Amsterdam HIV). Although these studies had different designs and were 
conducted on different study populations, a broad theme was consistent across studies: 1- Among 
ARV-naive patients, initiation of combination antiviral therapy in intennediate stage disease can 
provide clinical and survival benefits that are superior to ZDV alone; and 2-. among ~V-
experienced patients, delaying changing therapy until late or very late-stage disease senously 
reduces clinical efficacy of combination treatment. 
A number of antiretrovirals (nucleoside RT inhibitors, non-nucleoside RT inhibitors, 
protease inhibitors, and others) are currently being studied in combinations of 2, 3, or ~ore dru_gs. 
Use of measures of viral load, such as branched DNA (bDNA) and RNA polymerase cham reaction 
(PCR) assays, combined with studies on drug resistance development, will allow researchers to 
rapidly identify the most promising drug combination regimens. . . . 
Data presented using protease inhibitors in combination with several other RT inhib1to~ 
offered the most exciting combination treatment infonnation to date. Initial data suggests that this 
combination will more completely suppress the virus than any antivirals we used in the past. The 
prevailing theme at the conference was that protease inhibitors in triple_ combination ~eatme~t (with 
2 RT inhibitors) may very well become the standard of care of HIV m the future, influencmg not 
only timing of therapy, but other issues like survival time, etc. (See front page article and insert 
for more detailed infonnation). 
Viral Load Testing Supported 
Research data presented in a number of studies indicated that measures of viral load in 
the bloodstream are better predictors of an infected persons' future health than any previous 
laboratory test or calculation used to make a prognosis. Changes in viral load precede change~ in 
CD4 cell count by 1-2 years and accurately predict disease progression. CD4 cell count and viral 
load-do not always correlate. For example: a patient can have a high CD4 count and a high viral 
load. This patient would have a poorer prognosis than a person who had a high CD4 count a?d 
a low viral load. HIV RNA measurements were correlated with clinical endpoints and overall trial 
results in a virology substudy in 391 of the 2467 patients enrolled in ACTG 175. A tenfold (I-log) 
increase in viral load resulted in a 3.83 fold (aggregate endpoint) increased risk of AIDS, death, 
or 50% decline in CD4 cell counts, a 5.77-fold increase in risk of AIDS or death, and a 6.0 - fold 
increase in risk of death. 
It was noted that plasma HIV RNA measurements will be useful for patient management (with 2 
gathered 2 wks to I month apart to establish a baseline). However, the proportion of tream:ient 
effect explained by change in viral load has not yet been defmed. A general theme ~t van~us 
presentations in the conference was that viral load needs to be decreased as much as possible, with 
a goal being to get a patient to <10,000 copies/ml or even aviremic.Several investigators sounded 
a note of caution that viral burden in the blood may not reflect viral pathogenesis throughout the 
body. In particular, since lymph nodes have been identified as the p~ciple site_ of viral replicati~n 
for much of the disease course, investigators have continued to examme HIV m lymph nodes via 
biopsies, and compared viral loads with plasma HIV RNA levels. Results have varied, with several 
studies reporting no parallel lymph node responses or slower viral clearance from nodes. Further 
study is needed in this area. 
New Drugs, cont. 
Protease Inhibitors Spark Excitement 
Protease inhibitors, a new class of antiretroviral 
drug that act to prevent the fonnation of 
infectious virions at a point in viral assembly 
appear to present a very promising advance in 
antiretroviral treatment. Saquinavir, the first 
protease inhibitor to be released, has been on 
the market for several months. Two additional 
protease inhibitors, indinavir (Merck) and 
ritonavir (Abbot) were approved by the FDA 
on March I, 1996. These drugs appear to be 
additive or synergistic when combined with 
reverse transcriptase inhibitors, and based on 
their effect on HIV plasma RNA levels, appear 
to be more potent than reverse transcriptase 
inhibitors. Resistance to protease inhibitors 
does not overlap with known genotypic 
resistance to RT inhibitors, and their toxicities 
are not overlapping. In fact, toxicity to 
protease inhibitors has been minimal, limited to 
mild GI intolerance, circumoral paresthesias, 
nephrolithiasis, and dysgeusia, and mild 
elevation in transaminase and triglyceride 
levels. 
So what should be our strategy now that these 
drugs are becoming available? Guidelines do 
not yet exist. Preliminary data suggests that 
ritonavir and indinavir are the most potent 
protease inhibitors. Ritonavir decreased 
mortality and onset of opportunist infections by 
1/2 in a group of over 1,000 late stage patients. 
Indinavir, when combined with AZT+3TC, 
rendered 24 of 26 patients aviremic when 
plasma RNA was measured. It is reasonable to 
believe that very low plasma HIV RNA levels 
will be associated with delayed disease 
progression. Therefore, these preliminary 
results have sparked excitement among 
clinicians caring for person, with HIV. 
Where does this infonnation leave us 
at this point? For now, initiation of therapy is 
still usually begun in patients with CD4 counts 
of <500, with the exception that some 
clinicians now favor treating patients with 
higher CD4 counts if they have a high viral 
load documented on 2 or more occasions. 
Secondly, recent data suggests that when 
therapy is initiated, combination therapy 
(AZT+DDI or AZT+DDC) is probably 
preferable to monotherapy. Based on the 
results of ACTG 175, monotherapy with DDI 
would be an acceptable alternative. The use of 
3TC with AZT appears to be another option 
that is well tolerated. Whether or not to add 
the new protease inhibitors early in therapy, or 
to reserve them for patients when other 
therapies fail to suppress viral load or to 
stabilize CD4 counts, is an open question. In 
general, toxicity of these agents appears to be 
low, but data on their interactions with other 
commonly used drugs in HIV is still sparse. 
Principles of Protease Inhibitor Use 
1. Start with highest appropriate dose and avoid dose adjustment if possible. 
2. Use in combination with other agents. 
3. Be aware of drug interactions (see other side of insert). 
New Antiviral Agents & Combinations 
Class Drug Usual Dosage Side Effects Effective Regimens 
RT Inhibitors 
Nucleoside AZT 200 mgtid Bone marrow suppression AZT 
(Zidovudine) Myopathy AZT+DDI 
GI symptoms AZT+DDC 
AZT+3TC 
All regimens with or without 
a protease inhibitor. 
DOI 200mgbid Pancreatitis DOI 
( didanosine) GI intolerance DDI+AZT 
Neuropathy DOI + D4T (Z?) 
All regimens with or without 
a protease inhibitor. 
DOC 0.75 mg tid Pancreatitis (rare) DOC 
( deoxycytidine) Neuropathy DDC+AZT 
Oral I esophageal ulcers All regimens with or without 
a protease inhibitor. 
D4T 40 mg bid Neuropathy D4T 
(Stavudine) D4T+DDI(?) 
3TC 150 mg bid GI intolerance 3TC+AZT 
(Lamivudine) Neutropenia (rare) AZT + 3TC + Protease 
Inhibitor 
[Non-Nucleoside Delavirdine 400 mgtid Rash Delavirdine + AZT 
(available through GI intolerance Delavirdine + DOI 
compassionate use Delavirdine + AZT + DOI 
only) or DOC 
Protease Inhibitors 
Saquinavir 600 mg bid GI intolerance Saquinavir + 1 or 2 RT 
(with food) Drug interactions inhibitors 
Ritonavir 600 mgtid GI intolerance Ritonavir + 1 or 2 RT 
(with food) Drug interactions inhibitors 
lndinavir 800 mg tid GI intolerance AZT + 3TC + lndinavir 
(with food) Nephrolithiasis (2-5%) Indinavir + 1 or 2 RT 
Drug interactions inhibitors 
Analgesic 
Cardiovascular 
(Antiarrhythmic) 
Antimycobacterial 
Cardiovascular 
Potential Drug Interactions - Ritonavir 
(Data on lndinavir Not Available) 
Avoid Alternative Treatment 
meperidine (Demoral) acetaminophen (Tylenol) 
piroxicam (F eldene) .. aspmn 
propoxyphene (Darvon) oxycodone (Percodan) 
amiodarone (Cordarone) 
encainide (Enkaid) 
flecainide (Tambocor) 
propafenone (Rythmol) 
quinidine 
rifabutin (Mycobutin) clarithromycin (Biaxin) 
ethambutol (Myambutol) 
bepridil (Vascor) 
( calcium channel blocker) 
Cold & Allergy 
(antihistamine) 
Gastrointestinal 
Psychotropic 
(antidepressant) 
Psychotropic 
(sedative/hypnotic) 
astemizole (Hismanal) loratadine (Claritin) 
terfenadine (Seldane) 
cisapride (Propulsid) 
bupropion (Wellbutrin) fluoxetine (Prozac) 
desipramine (N orpramin) 
alprazolam (Xanax) temazepam (Restoril) 
clorazepate (Tranxene) lorazepam (Ativan) 
diazepam (Valium) 
estazolam (Prosam) 
fluroepam (Dalmane) 
midazolam (Versed) 
triazolam (Halcion) 
zolpidem (Ambien) 
If you have questions regarding the use or 
side effects of Protease Inhibitors call the 
AIDS Consultation Service 
Treatment Information Line @ 
1-800-871-2701 
HIV Patient Assistance Programs 
Encouragement over new drug therapies for persons with HIV is often met with frustration 
when faced with the financial cost. It can be overwhelming for people to figure out on their own 
how to access medication assistance programs, when and how to apply for Medicaid, and what they 
will be expected to pay for themselves. A person with HIV or AIDS could easily deplete a lifetime 
of savings just in paying for medications. People with HIV/AIDS benefit from having their own 
case manager or social worker to assist them in accessing whatever assistance they are entitled to. 
Most private insurers offer prescription drug coverage that includes coverage for 
HIV I AIDS drugs. A person who has Medicaid coverage will qualify for medication assistance with 
any FDA approved drug. The Maine Dept of Human Services' Drug Reimbursement Program (207-
287-5060) provides reimbursement for some medication for patients with HIV who meet financial 
requirements and have no other way to pay for prescriptions, or are pending Medicaid coverage or 
reimbursement by an insurance plan. Drugs covered under this program include: Pentamidine, 
AZT, DDI, DDC, D4T, Acyclovir, Fluconazol, and Bactrim. 
Following is a list of the pharmaceutical companies who offer HIV patient assistance 
programs for some of the newer medications mentioned in this newsletter. 
These pharmaceutical companies will supply patients with drug if they meet income guidelines and 
are not eligible for or have exhausted Medicare, Medicaid, Ryan White Funds, and all other third 
party coverage. Applications must be completed by a physician with DEA number. 
Epivir (JTC), AZT, Acyclovir 
Glaxo Wellcome Co., Patient Assistance Program 
PO Box 52035 
Phoenix, AZ 85072 
l -800-513-3028 
D4T (Stavudine), DDI 
Bristol Meyers Squibb 
Patient Assistance Program 
1800 Robert Fulton Drive 
Raston, VA 22091 
l-800-272-4878 
Norvir (Ritonavir) 
Abbott Pharmaceutical Co. 
Patient Assistance Program 
l-800-688-9118 
lnvirase (Squinavir), DDC, 
Roche HIV Therapy Assistance Program 
340 Kingsland Street 
Nutley, NJ 07110 
l-800-282-7780 
Crixivan (lnidinavir) 
Merck Pharmaceutical Co. 
Patient Assistance Program 
PO Box 4 (WP35-258) 
West Point, PA 19468-0004 
l-800-672-6372 
Community Counseling Center's New 
AIDS Family Therapy Initiate 
Helps Persons with HIV and Their Families 
Community Counseling Center's AIDS Family Therapy Initiative is a new, comprehensive family 
treatment program for Cumberland County residents who have been affected by the HIV/AIDS 
virus. This program includes family members, friends, and caregivers. The Initiative is designed 
to help individuals and their families deal with the many implications of HIV disease. 
Families affected by HIV frequently handle very difficult issues such as loss and impending loss, 
the unpredictability of the disease, and the sometimes extraordinary demands of providing physical 
and emotional care for persons with HIV. Through this program, individual and group therapy is 
provided in a safe, supportive environment in which each family member can communicate, express 
feelings, and develop helpful ways of dealing with stress. 
Any family member or friend who is part of a person with HIV/AIDS caregiving support network 
can participate in the program (the persons with HIV/AIDS does not have to live in Cumberland 
County). For more information, contact the AIDS Family Therapy Initiative Coordinator at 
Community Counseling Center, (207) 874-1030. Community Counseling Center is a United Way 
agency. 
Delavirdine cont. 
The general consensus is that DL V 
used in combination with AZT provides an 
effective and sustained decrease in viral load 
(.5 log) and a smaller but sustained increase in 
CD4 cell count (20-30 cells). The AIDS 
Consultation Service has patients who have 
been enrolled in this study for almost 2 years 
now. We · are pleased to see that the initial 
results demonstrate a benefit of delavirdine 
therapy. 
2. DDI + placebo vs. DDI + DLV 400mg 
tid: Preliminary results of this arm showed 
that DL V in combination with DDI decreased 
viral load initially .8-.9 log (vs. DDI to .4 log 
alone), with a .5 log sustained decrease x60 
weeks. ·There was a sustained CD4 cell count 
increase of 10-25 cells above baseline at 60 
weeks. However, although these results give 
evidence that the combination of DL V+DDI 
does suppress viral replication, it appears that 
this is so because AZT seems to delay 
resistance to DL V and vice versa. 
No changes are planned in the this 
protocol at this time. 
3. Protocol #23 Salvage Protocol: DLV 
400mg tid + AZT 300 mg + DDI or DDC -
Triple Combination Treatment: The results 
of this arm of the study (with data available on 
200 patients) showed that the great majority of 
these patients were AZT experienced for l-3 
years, and DDI experienced for 3-24 months. 
patients could roll over into this protocol only 
if they had a 50% decrease in CD4 cells, an 
AIDS defining illness, or upon trial completion. 
The results showed that DL V works in triple 
combination therapy, with the strongest 
combination being DL V+AZT+DDI. These 
Patients had a l 0-40 cell increase in CD4 cell 
counts and a 0.3-0.8 log decrease in viral RNA 
for ~ 24 weeks. It was also concluded that it 
is best to switch to 2 new drugs when going to 
triple combination therapy; the effect on CD4 
and viral load is greater with 2 new drugs. 
The DL V study provides the largest data base 
to date for HIV RNA PCR and bDNA viral 
load results. We look forward to further data 
analysis. Please note DL V is now available in 
Open Label by contacting UpJohn Pharmacia 
Co. 
World AIDS Cases 
U.S. AIDS Cases 
U.S. AIDS Deaths 
4,500,000* 
501,310 
311,381 
Maine AIDS Cases 712 
Maine AIDS Deaths 335 
Reported through 10/31/95 by CDC As reported through December 31, 1995 
Upcoming HIV/AIDS Educational Sessions 
April 23, 1996 Primary Care Management of HIV & Living with HIV 
Central Maine Medical Center, Lewiston Maine 
9:00 am - 12:00 pm 
Sandra Putnam, RN, MSN, FNP Nurse Coordinator, AIDS Consultation Service 
May 29, 1996 AIDS Consultation Service - HIV/AIDS Symposium 
Maine Medical Center, Portland Maine 
8:00 am - 4:00 pm 
Topics & Speakers Include: 
New Concepts in HIV and New Approaches to Antiviral Treatment 
Dr. Scott Hammer - New England Deaconess Hospital 
Primary Care Management - Applying the Newest Science to Disease Management 
Dr. Harvey Makadon - Beth Israel Hospital 
Opportunistic Infection Management 
Dr. Howard Heller - Mass General 
Afternoon Breakout Clinical Tracks Include: 
Maine Medical Center's 
AIDS Consultation Service 
22 Bramhall Street 
Portland Maine 04102 
1. Pain Control, Depression, & Dementia - Challenges to Management in HIV 
2. HIV in Women 
3. HIV Update for People Living with AIDS - Answering All Your Questions 
(Panel presentation I discussion) 
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